Affected by the news, Zhifei biological shares rose more than 8% in the intraday, and other new crown vaccine stocks also followed.
On October 22, Zhifei biology and Institute of Microbiology of Chinese Academy of Sciences uncovered the key data of safety and immunogenicity in phase I and II clinical trials of the new coronavirus vaccine, and the results were in line with expectations. The safety and immunogenicity of the new coronavirus vaccine showed good safety and immunogenicity. The positive conversion rate of sars-cov-2 virus neutralizing antibody reached more than 96%. Further clinical trials can be carried out.
On November 4, the drug examination center of the State Drug Administration held a communication and consultation meeting on the phase III clinical trial protocol of Zhifei biological recombinant new crown vaccine, and the phase III clinical protocol was improved and confirmed.
The vaccine is the first recombinant subunit new crown vaccine in China, and it is also the fifth candidate vaccine to enter phase III clinical trial in China.
In addition, the inactivated vaccines from Wuhan Institute of biology of sinopharma group, the Beijing Institute of biology, the adenovirus vector vaccine developed by the Academy of Military Sciences and kangxinuo company, and the inactivated vaccines of Beijing Kexing Zhongwei Biological Technology Co., Ltd. (hereinafter referred to as Kexing Zhongwei) have entered the third phase of clinical practice and are progressing smoothly.
It is reported that two new crown inactivated vaccines under Sinopharm group are in phase III clinical trials in UAE, Bahrain, Egypt, Jordan, Morocco, Peru, Argentina and other countries. More than 50000 volunteers have been vaccinated. The sample population has covered 125 nationalities, and the progress in all aspects is leading the world. According to the vaccination situation in China, hundreds of thousands of people have been vaccinated with the two vaccines, and there are no serious adverse reactions. 56000 people left the country after vaccination, and none of them were infected. At the end of last month, Shi Shengyi, deputy general manager of Sinopharm group, revealed in an interview that Sinopharm group had submitted an application for listing the new crown vaccine to the State Food and drug administration.
The international phase III clinical trial of recombinant new coronary vaccine (adenovirus vector) jointly developed by conconor biology and the Academy of Military Sciences has been launched in Mexico in early November and has been vaccinated. Earlier, conchino bio announced that it would provide 35 million doses of new coronal vaccine to Mexico from the end of 2020 to 2021.
At the 2020 first China Health Science and technology innovation and Development Conference on November 28, Yin Weidong, chairman of Kexing holding Biotechnology Co., Ltd., said that the phase III clinical study of kelefu, a new coronal vaccine developed by ZTE, is expected to complete the mid-term analysis in early December.
According to Xinhua news agency, vice premier sun Chunlan and State Councilor Wang Yong investigated the research and development and production preparation of new coronavirus vaccine in Beijing on December 2. They also visited the China Academy of food and drug control, Beijing Kexing company and Sinopharm Beijing company, in-depth understanding of the new coronavirus vaccine research and development, production workshop construction, preparation for batch issuance, etc., and fully affirmed the vaccine The achievements of our work.
Sun Chunlan pointed out that at present, 14 vaccines from 5 technical routes have entered clinical trials, among which 5 vaccines are conducting phase III clinical trials according to the procedures and standards, and the work of emergency use and production preparation has been promoted orderly.